| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCL5; LAZ3; BCL6A; ZNF51; ZBTB27 |
| Entrez GeneID | 604 |
| clone | 7A6D1 |
| WB Predicted band size | 78.8KDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BCL6 (AA: 507-706) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与BCL6抗体相关的文献示例(内容基于公开研究概括)：
---
1. **文献名称**：*BCL-6 protein is expressed in germinal-center B cells*
**作者**：Cattoretti G, et al.
**摘要**：该研究首次通过特异性抗体证实BCL6蛋白在正常生发中心B细胞中高表达，并发现其在弥漫大B细胞淋巴瘤(DLBCL)中的异常表达，为淋巴瘤分类提供了分子标志物。
---
2. **文献名称**：*BCL6 regulates differentiation and survival of germinal center B cells*
**作者**：Ye BH, et al.
**摘要**：通过抗体免疫沉淀和基因敲除实验，揭示了BCL6通过抑制DNA损伤反应和分化相关基因维持生发中心B细胞的存活与增殖，为靶向BCL6的淋巴瘤治疗奠定理论基础。
---
3. **文献名称**：*BCL6 controls the DNA damage response via transcriptional regulation of ATR*
**作者**：Polo JM, et al.
**摘要**：研究发现BCL6通过抑制ATR基因表达延缓DNA损伤修复，解释了其在B细胞耐受基因组不稳定性中的作用，并利用抗体染色验证了BCL6与DNA修复通路的关联。
---
4. **文献名称**：*Mutations of BCL6 in lymphoid neoplasms*
**作者**：Pasqualucci L, et al.
**摘要**：通过免疫组化结合测序分析，揭示了BCL6基因突变导致其蛋白稳定性改变，促进淋巴瘤发生，强调BCL6抗体在临床病理诊断中的重要性。
---
注：以上文献信息为示例性质，具体引用请核对PubMed或期刊数据库获取原文。
BCL6 (B-cell lymphoma 6) is a transcriptional repressor protein encoded by the *BCL6* gene, primarily expressed in germinal center B-cells and certain T-cell subsets. It plays a critical role in regulating lymphocyte differentiation, immune response, and lymphomagenesis. BCL6 suppresses genes involved in DNA damage response, cell cycle arrest, and apoptosis, enabling germinal center B-cells to undergo rapid proliferation and somatic hypermutation without triggering stress-induced cell death. Dysregulation of BCL6. due to chromosomal translocations, mutations, or overexpression, is strongly associated with B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
BCL6 antibodies are essential tools in research and diagnostics. In immunohistochemistry (IHC), they help identify BCL6 protein expression in tissue samples, aiding in lymphoma classification and prognosis. Flow cytometry and Western blotting utilize these antibodies to analyze BCL6 expression levels in cell populations. Additionally, BCL6 antibodies are employed in studying mechanisms of oncogenesis, transcriptional regulation, and interactions with co-repressors like SMRT and NCOR. Recent therapeutic strategies targeting BCL6 in cancers, such as small-molecule inhibitors or peptide disruptors, further underscore its clinical relevance. However, interpretation requires caution, as BCL6 expression can also occur in non-neoplastic lymphoid tissues, necessitating context-specific analysis.
×
